Background:
Sleep disturbance is a common feature of rheumatic diseases but often poorly identified by physicians[1,2]. Patient reported outcome measures may help identify sleep disturbance in patients with rheumatic arthritis and psoriatic arthritis[3].
Aims
This study will compare the performance of two multidimensional questionnaires to a validated symptom-specific questionnaire, in their ability to detect sleep disturbance in patients with Rheumatoid Arthritis and Psoriatic Arthritis.
In particular, the aims of the study are to:
1. Determine the prevalence of sleep disturbance in our cohort
2. Examine the sensitivity and specificity of the sleep-disturbance component of the multidimensional questionnaires, in order to determine whether they are feasible and practical to be used in clinical practice instead of a symptom-specific questionnaire
3. To explore the relationship between disease activity and sleep disturbance, as well as the impact of co-exisiting fibromyalgia, anxiety and/or depression.
Methods:
This is a cross sectional observation study undertaken in the Rheumatology Outpatient Department of Liverpool Hospital, NSW, Australia. All patients attending the clinic were asked to complete the Multidimensional Health Assessment Questionnaire (MDHAQ), the Patient Reported Outcome Measure Information System (PROMIS-29), Pittsburgh Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS) and the Fibromyalgia Survey Questionnaire. The treating doctor completed the RheuMetric Physician Checklist for each patient. The diagnosis for all patients was screened, and those with documented Rheumatoid Arthritis or Psoriatic Arthritis were included in the study. Scores for the sleep disturbance component of the multidimensional questionnaires (MDHAQ and PROMIS-29) were compared to the scores on the PSQI to examine whether the multidimensional questionnaires adequately detect these symptoms in this population. The Fibromyalgia Survey Questionnaire and HADS were used to analyse whether the presence of fibromyalgia, anxiety and depression affected the rate of detection of these symptoms.
Results:
Early descriptive results will be presented at the meeting.